Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 421

1.

Statin therapy increases lipoprotein(a) levels.

Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL.

Eur Heart J. 2019 May 20. pii: ehz310. doi: 10.1093/eurheartj/ehz310. [Epub ahead of print]

PMID:
31111151
2.

ApoC-III ASO Promotes Tissue LPL Activity in Absence of ApoE-Mediated TRL Clearance.

Ramms B, Patel S, Nora C, Pessentheiner AR, Chang MW, Green CR, Golden GJ, Secrest P, Krauss RM, Metallo CM, Benner C, Alexander VJ, Witztum JL, Tsimikas S, Esko JD, Gordts PLSM.

J Lipid Res. 2019 May 14. pii: jlr.M093740. doi: 10.1194/jlr.M093740. [Epub ahead of print]

3.

Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis.

Zheng KH, Tsimikas S, Pawade T, Kroon J, Jenkins WSA, Doris MK, White AC, Timmers NKLM, Hjortnaes J, Rogers MA, Aikawa E, Arsenault BJ, Witztum JL, Newby DE, Koschinsky ML, Fayad ZA, Stroes ESG, Boekholdt SM, Dweck MR.

J Am Coll Cardiol. 2019 May 7;73(17):2150-2162. doi: 10.1016/j.jacc.2019.01.070.

4.

Apolipoprotein Profiles in Very Preterm and Term-Born Preschool Children.

Posod A, Pechlaner R, Yin X, Burnap SA, Kiechl SJ, Willeit J, Witztum JL, Mayr M, Kiechl S, Kiechl-Kohlendorfer U.

J Am Heart Assoc. 2019 Apr 16;8(8):e011199. doi: 10.1161/JAHA.118.011199.

5.

RNA-Targeted Therapeutics.

Crooke ST, Witztum JL, Bennett CF, Baker BF.

Cell Metab. 2019 Feb 5;29(2):501. doi: 10.1016/j.cmet.2019.01.001. No abstract available.

PMID:
30726759
6.

A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma.

Gonen A, Choi SH, Miu P, Agatisa-Boyle C, Acks D, Taylor AM, McNamara CA, Tsimikas S, Witztum JL, Miller YI.

J Lipid Res. 2019 Feb;60(2):436-445. doi: 10.1194/jlr.D090852. Epub 2018 Dec 18.

PMID:
30563909
7.

CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice.

Riopel M, Vassallo M, Ehinger E, Pattison J, Bowden K, Winkels H, Wilson M, de Jong R, Patel S, Balakrishna D, Bilakovics J, Fanjul A, Plonowski A, Larson CJ, Ley K, Cabrales P, Witztum JL, Olefsky JM, Lee YS.

Mol Metab. 2019 Feb;20:89-101. doi: 10.1016/j.molmet.2018.11.011. Epub 2018 Dec 2.

8.

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.

Blom DJ, O'Dea L, Digenio A, Alexander VJ, Karwatowska-Prokopczuk E, Williams KR, Hemphill L, Muñiz-Grijalvo O, Santos RD, Baum S, Witztum JL.

J Clin Lipidol. 2018 Sep - Oct;12(5):1234-1243.e5. doi: 10.1016/j.jacl.2018.05.013. Epub 2018 May 31.

9.

Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.

van Capelleveen JC, Lee SR, Verbeek R, Kastelein JJP, Wareham NJ, Stroes ESG, Hovingh GK, Khaw KT, Boekholdt SM, Witztum JL, Tsimikas S.

J Clin Lipidol. 2018 Nov - Dec;12(6):1493-1501.e11. doi: 10.1016/j.jacl.2018.08.010. Epub 2018 Aug 29.

PMID:
30249512
10.

Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size.

Tsimikas S, Fazio S, Viney NJ, Xia S, Witztum JL, Marcovina SM.

J Clin Lipidol. 2018 Sep - Oct;12(5):1313-1323. doi: 10.1016/j.jacl.2018.07.003. Epub 2018 Jul 20.

PMID:
30100157
11.

Publisher Correction: Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice.

Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Määttä A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL.

Nature. 2018 Sep;561(7724):E43. doi: 10.1038/s41586-018-0313-x.

PMID:
30013121
12.

Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice.

Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Määttä A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL.

Nature. 2018 Jun;558(7709):301-306. doi: 10.1038/s41586-018-0198-8. Epub 2018 Jun 6. Erratum in: Nature. 2018 Sep;561(7724):E43.

13.

Oxidation-specific epitopes restrain bone formation.

Ambrogini E, Que X, Wang S, Yamaguchi F, Weinstein RS, Tsimikas S, Manolagas SC, Witztum JL, Jilka RL.

Nat Commun. 2018 Jun 6;9(1):2193. doi: 10.1038/s41467-018-04047-5.

14.

Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids.

Yeang C, Hasanally D, Que X, Hung MY, Stamenkovic A, Chan D, Chaudhary R, Margulets V, Edel AL, Hoshijima M, Gu Y, Bradford W, Dalton N, Miu P, Cheung DY, Jassal DS, Pierce GN, Peterson KL, Kirshenbaum LA, Witztum JL, Tsimikas S, Ravandi A.

Cardiovasc Res. 2019 Jan 1;115(1):179-189. doi: 10.1093/cvr/cvy136.

PMID:
29850765
15.

Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide.

Narayanan P, Shen L, Curtis BR, Bourdon MA, Nolan JP, Gupta S, Hoffmaster C, Zhou F, Christian B, Schaubhut JL, Greenlee S, Burel SA, Witztum JL, Engelhardt JA, Henry SP.

Toxicol Sci. 2018 Aug 1;164(2):613-626. doi: 10.1093/toxsci/kfy119.

PMID:
29846725
16.

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study.

Davidson M, Stevenson M, Hsieh A, Ahmad Z, Roeters van Lennep J, Crowson C, Witztum JL.

J Clin Lipidol. 2018 Jul - Aug;12(4):898-907.e2. doi: 10.1016/j.jacl.2018.04.009. Epub 2018 Apr 26.

17.

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.

Hegele RA, Berberich AJ, Ban MR, Wang J, Digenio A, Alexander VJ, D'Erasmo L, Arca M, Jones A, Bruckert E, Stroes ES, Bergeron J, Civeira F, Witztum JL, Gaudet D.

J Clin Lipidol. 2018 Jul - Aug;12(4):920-927.e4. doi: 10.1016/j.jacl.2018.03.093. Epub 2018 Apr 4.

18.

RNA-Targeted Therapeutics.

Crooke ST, Witztum JL, Bennett CF, Baker BF.

Cell Metab. 2018 Apr 3;27(4):714-739. doi: 10.1016/j.cmet.2018.03.004. Review. Erratum in: Cell Metab. 2019 Feb 5;29(2):501.

19.

Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.

Viney NJ, Yeang C, Yang X, Xia S, Witztum JL, Tsimikas S.

J Clin Lipidol. 2018 May - Jun;12(3):702-710. doi: 10.1016/j.jacl.2018.02.014. Epub 2018 Mar 1.

PMID:
29574075
20.

Massively Parallel Sequencing of Peritoneal and Splenic B Cell Repertoires Highlights Unique Properties of B-1 Cell Antibodies.

Prohaska TA, Que X, Diehl CJ, Hendrikx S, Chang MW, Jepsen K, Glass CK, Benner C, Witztum JL.

J Immunol. 2018 Mar 1;200(5):1702-1717. doi: 10.4049/jimmunol.1700568. Epub 2018 Jan 29.

21.

PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis.

Senders ML, Que X, Cho YS, Yeang C, Groenen H, Fay F, Calcagno C, Meerwaldt AE, Green S, Miu P, Lobatto ME, Reiner T, Fayad ZA, Witztum JL, Mulder WJM, Pérez-Medina C, Tsimikas S.

J Am Coll Cardiol. 2018 Jan 23;71(3):321-335. doi: 10.1016/j.jacc.2017.11.036.

22.

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L.

J Am Coll Cardiol. 2018 Jan 16;71(2):177-192. doi: 10.1016/j.jacc.2017.11.014. Review.

23.

Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study.

Naka KK, Bechlioullis A, Marini A, Sionis D, Vakalis K, Triantis G, Wilkins L, Rogus J, Kornman KS, Witztum JL, Doucette-Stamm L, Michalis LK, Tsimikas S.

J Clin Lipidol. 2018 Mar - Apr;12(2):338-347. doi: 10.1016/j.jacl.2017.12.004. Epub 2017 Dec 19.

PMID:
29310992
24.

Plasma Proteomics for Epidemiology: Increasing Throughput With Standard-Flow Rates.

Yin X, Baig F, Haudebourg E, Blankley RT, Gandhi T, Müller S, Reiter L, Hinterwirth H, Pechlaner R, Tsimikas S, Santer P, Willeit J, Kiechl S, Witztum JL, Sullivan A, Mayr M.

Circ Cardiovasc Genet. 2017 Dec;10(6). pii: e001808. doi: 10.1161/CIRCGENETICS.117.001808.

PMID:
29237681
25.

Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials.

Marcovina SM, Viney NJ, Hughes SG, Xia S, Witztum JL, Tsimikas S.

J Clin Lipidol. 2018 Jan - Feb;12(1):122-129.e2. doi: 10.1016/j.jacl.2017.10.024. Epub 2017 Nov 2.

PMID:
29174389
26.

Lipoprotein(a) Associated Molecules are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis.

Torzewski M, Ravandi A, Yeang C, Edel A, Bhindi R, Kath S, Twardowski L, Schmid J, Yang X, Franke UFW, Witztum JL, Tsimikas S.

JACC Basic Transl Sci. 2017 Jun;2(3):229-240. doi: 10.1016/j.jacbts.2017.02.004. Epub 2017 Jun 26.

27.

Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up.

Hartikainen J, Hassinen I, Hedman A, Kivelä A, Saraste A, Knuuti J, Husso M, Mussalo H, Hedman M, Rissanen TT, Toivanen P, Heikura T, Witztum JL, Tsimikas S, Ylä-Herttuala S.

Eur Heart J. 2017 Sep 1;38(33):2547-2555. doi: 10.1093/eurheartj/ehx352. Erratum in: Eur Heart J. 2018 May 7;39(18):1652.

28.

Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study.

Kamstrup PR, Hung MY, Witztum JL, Tsimikas S, Nordestgaard BG.

Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1570-1578. doi: 10.1161/ATVBAHA.116.308761. Epub 2017 Jun 1.

29.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S.

N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24.

30.

Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events.

Prasad A, Clopton P, Ayers C, Khera A, de Lemos JA, Witztum JL, Tsimikas S.

Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1213-1221. doi: 10.1161/ATVBAHA.117.309101. Epub 2017 May 4.

31.

Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.

van Capelleveen JC, Bernelot Moens SJ, Yang X, Kastelein JJP, Wareham NJ, Zwinderman AH, Stroes ESG, Witztum JL, Hovingh GK, Khaw KT, Boekholdt SM, Tsimikas S.

Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1206-1212. doi: 10.1161/ATVBAHA.117.309007. Epub 2017 May 4.

32.

Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis.

Saleheen D, Haycock PC, Zhao W, Rasheed A, Taleb A, Imran A, Abbas S, Majeed F, Akhtar S, Qamar N, Zaman KS, Yaqoob Z, Saghir T, Rizvi SNH, Memon A, Mallick NH, Ishaq M, Rasheed SZ, Memon FU, Mahmood K, Ahmed N, Frossard P, Tsimikas S, Witztum JL, Marcovina S, Sandhu M, Rader DJ, Danesh J.

Lancet Diabetes Endocrinol. 2017 Jul;5(7):524-533. doi: 10.1016/S2213-8587(17)30088-8. Epub 2017 Apr 10. Erratum in: Lancet Diabetes Endocrinol. 2017 Sep;5(9):e6.

33.

The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study.

Davidson M, Stevenson M, Hsieh A, Ahmad Z, Crowson C, Witztum JL.

Expert Rev Cardiovasc Ther. 2017 May;15(5):415-423. doi: 10.1080/14779072.2017.1311786. Epub 2017 Apr 4.

PMID:
28338353
34.

Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial.

Capoulade R, Chan KL, Mathieu P, Bossé Y, Dumesnil JG, Tam JW, Teo KK, Yang X, Witztum JL, Arsenault BJ, Després JP, Pibarot P, Tsimikas S.

Atherosclerosis. 2017 May;260:1-7. doi: 10.1016/j.atherosclerosis.2017.03.013. Epub 2017 Mar 9.

PMID:
28319871
35.

Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.

Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P, Oberhollenzer F, Egger G, Witztum JL, Alexander VJ, Willeit J, Kiechl S, Mayr M.

J Am Coll Cardiol. 2017 Feb 21;69(7):789-800. doi: 10.1016/j.jacc.2016.11.065.

36.

The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.

Crooke ST, Baker BF, Witztum JL, Kwoh TJ, Pham NC, Salgado N, McEvoy BW, Cheng W, Hughes SG, Bhanot S, Geary RS.

Nucleic Acid Ther. 2017 Jun;27(3):121-129. doi: 10.1089/nat.2016.0650. Epub 2017 Feb 1.

37.

Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.

Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; SPARCL Trial Investigators.

J Am Coll Cardiol. 2017 Jan 17;69(2):147-158. doi: 10.1016/j.jacc.2016.10.057.

38.

Cholesterol Accumulation in CD11c+ Immune Cells Is a Causal and Targetable Factor in Autoimmune Disease.

Ito A, Hong C, Oka K, Salazar JV, Diehl C, Witztum JL, Diaz M, Castrillo A, Bensinger SJ, Chan L, Tontonoz P.

Immunity. 2016 Dec 20;45(6):1311-1326. doi: 10.1016/j.immuni.2016.11.008.

39.

LPA Gene, Ethnicity, and Cardiovascular Events.

Lee SR, Prasad A, Choi YS, Xing C, Clopton P, Witztum JL, Tsimikas S.

Circulation. 2017 Jan 17;135(3):251-263. doi: 10.1161/CIRCULATIONAHA.116.024611. Epub 2016 Nov 9.

40.

Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease.

Nsaibia MJ, Mahmut A, Boulanger MC, Arsenault BJ, Bouchareb R, Simard S, Witztum JL, Clavel MA, Pibarot P, Bossé Y, Tsimikas S, Mathieu P.

J Intern Med. 2016 Nov;280(5):509-517. doi: 10.1111/joim.12519. Epub 2016 May 30.

41.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S.

Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21.

PMID:
27665230
42.

Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia.

Duell PB, Santos RD, Kirwan BA, Witztum JL, Tsimikas S, Kastelein JJP.

J Clin Lipidol. 2016 Jul-Aug;10(4):1011-1021. doi: 10.1016/j.jacl.2016.04.013. Epub 2016 May 9.

PMID:
27578134
43.

Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.

van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LA, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, Stroes ES.

Circulation. 2016 Aug 23;134(8):611-24. doi: 10.1161/CIRCULATIONAHA.116.020838. Epub 2016 Aug 5.

44.

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD.

J Clin Invest. 2016 Aug 1;126(8):2855-66. doi: 10.1172/JCI86610. Epub 2016 Jul 11.

45.

Innate sensing of oxidation-specific epitopes in health and disease.

Binder CJ, Papac-Milicevic N, Witztum JL.

Nat Rev Immunol. 2016 Aug;16(8):485-97. doi: 10.1038/nri.2016.63. Epub 2016 Jun 27. Review.

PMID:
27346802
46.

Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).

Yeang C, Hung MY, Byun YS, Clopton P, Yang X, Witztum JL, Tsimikas S.

J Clin Lipidol. 2016 May-Jun;10(3):594-603. doi: 10.1016/j.jacl.2016.01.005. Epub 2016 Mar 8.

PMID:
27206947
47.

Sialic Acid-Binding Immunoglobulin-like Lectin G Promotes Atherosclerosis and Liver Inflammation by Suppressing the Protective Functions of B-1 Cells.

Gruber S, Hendrikx T, Tsiantoulas D, Ozsvar-Kozma M, Göderle L, Mallat Z, Witztum JL, Shiri-Sverdlov R, Nitschke L, Binder CJ.

Cell Rep. 2016 Mar 15;14(10):2348-61. doi: 10.1016/j.celrep.2016.02.027. Epub 2016 Mar 3.

48.

Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance.

Harmon DB, Srikakulapu P, Kaplan JL, Oldham SN, McSkimming C, Garmey JC, Perry HM, Kirby JL, Prohaska TA, Gonen A, Hallowell P, Schirmer B, Tsimikas S, Taylor AM, Witztum JL, McNamara CA.

Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):682-91. doi: 10.1161/ATVBAHA.116.307166. Epub 2016 Feb 11.

49.

Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.

Yang X, Lee SR, Choi YS, Alexander VJ, Digenio A, Yang Q, Miller YI, Witztum JL, Tsimikas S.

J Lipid Res. 2016 Apr;57(4):706-13. doi: 10.1194/jlr.M066399. Epub 2016 Feb 4.

50.

Lipoprotein (a): Coming of Age at Last.

Witztum JL, Ginsberg HN.

J Lipid Res. 2016 Mar;57(3):336-9. doi: 10.1194/jlr.E066985. Epub 2016 Feb 2. Review. No abstract available.

Supplemental Content

Loading ...
Support Center